Navigation Links
Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
Date:11/5/2013

BALTIMORE, Nov. 5, 2013 /PRNewswire/-- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO).  Her responsibilities include managing the Company's business, clinical, financial, licensing, and corporate development efforts.  Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008.

Under her leadership, Alba Therapeutics established a collaborative funding agreement on February 9, 2011 with Cephalon Pharmaceuticals (now Teva Pharmaceuticals) and has taken a leading role in advancing multiple clinical studies in Celiac Disease.  The company has conducted seven clinical trials in subjects with Celiac Disease and is currently conducting a large Phase IIb trial with the lead compound Larazotide Acetate. 

"Ms. Perrow brings a wealth of global experience and leadership with a proven track record of success in both biotech and pharmaceutical companies," said Bruce Peacock Co-Chairman of Alba. "Wendy is a key member of our leadership team, driving deal making as well as clinical and financial strategy and her experience in leading successful research and development and commercial infrastructures has been invaluable to Alba."

Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global and U.S. marketing for Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. A skilled marketer and business leader, she has led U.S. and Global initiatives for leading products that have significantly increased brand awareness and has launched medicines for unmet medical needs.

"Throughout her career, Ms. Perrow has demonstrated a true passion and commitment to bring new scientific advances and medications to help improve the standard of care for patients who have rare and serious conditions around the globe," said Matt Zuga Co-Chairman of Alba.  "With her broad experience and proven leadership across research, development, and commercialization, we have been able to accelerate Alba's mission to create medicines for patients with Celiac Disease.  Her breadth of experience in building successful companies and establishing strong collaborations is a tremendous asset to Alba Therapeutics as we continue to establish our leadership position in the Celiac Disease field."

Ms. Perrow holds a bachelor's degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business.

About Alba
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland.


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Navigation Systems Market 2014 - 2025" report to their ... ... reach USD 303.7 million by 2025. Increasing geriatric population prone ... demand for orthopedic navigation systems over the forecast period. Osteoarthritis ...
(Date:3/29/2017)... March 29, 2017  The Global Health Innovative ... partnership formed to battle infectious diseases around the ... million* that could help deliver a range of ... conditions. This latest round of ... clinical trial testing a pediatric formulation of a ...
(Date:3/29/2017)... BEACH, Calif. , March 29, 2017 /PRNewswire/ ... have recognized remote monitoring devices like  Soberlink Systems ...   The consensus paper, published in early 2017, ... practical and valuable in managing patient recovery." ... in the Journal of Addiction Medicine, detail a ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... main cause of hay fever in the United States, with an estimated 95 percent of ... July each year; with the worst time for sufferers being June and July. , ... provide an effective defense against grass pollen; they are proven in independent studies to trap ...
(Date:3/29/2017)... ... , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of ... used for thousands of years. , "The West has caught on, and has discovered ... to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
(Date:3/29/2017)... Rouge, Louisiana (PRWEB) , ... March 29, 2017 ... ... HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers ... at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested in receiving ... from Dr. Jamie Cameron, with or without a referral. The FASTBRACES system is ... Depending on each patient’s case, treatment with the FASTBRACES system could be completed ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
Breaking Medicine News(10 mins):